Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: Comparison to other dopamine receptor agonists

European Journal of Pharmacology

Volumn 312, Issue 1, 1996, Pages 35-44

  Piercey, Montford F ^a   Hoffmann, William E ^a   Smith, Martin W ^a   Hyslop, Deborah K ^a  

^a PFIZER INC   (United States)

Author keywords

D3 receptor; Dopamine neuronal firing; Dopamine receptor agonist; Pramipexole

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; BROMOCRIPTINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LISURIDE; PERGOLIDE; PRAMIPEXOLE; QUINPIROLE; RECEPTOR SUBTYPE; ROPINIROLE;

ANIMAL CELL; ARTICLE; CHO CELL; DOPAMINERGIC NERVE CELL; DRUG RECEPTOR BINDING; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION; SUBSTANTIA NIGRA;

EID: 0030593744     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(96)00454-2     Document Type: Article

References (55)

1. Aghajanian, G.K. and B.S. Bunney, 1977, Dopamine "autoreceptors": Pharmacological characterization by microiontophoretic single cell recording studies, Naunyn-Schmiedeberg's Arch. Pharmacol. 297, 21.
2. 3 subtypes, Brain Res. 649, 95.
3. Bannon, J.J., A.A. Grace, B.S. Bunney and R.H. Roth, 1980, Evidence for an irreversible interaction of bromocriptine with central dopamine receptors, Naunyn-Schmiedeberg's Arch. Pharmacol. 312, 37.
4. 3 receptors, Br. J. Pharmacol. 110, 93P.
5. 3 dopamine receptor: pharmacologic properties and development of antibodies, J. Pharmacol. Exp. Ther. 264, 1002.
6. Bouthenet, M.L., E. Souil, M.P. Martres, P. Sokoloff and J.C. Schwartz, 1991, Localization of dopamine D3 receptors mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA, Brain Res. 564, 203.
7. Bunney, B.S., J.R. Walters, R.H. Roth and G.K. Aghajanian, 1973, Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity, J. Pharmacol. Exp. Ther. 185, 560.
8. 2 dopamine receptors appears necessary for full expression of postsynaptic effects of dopamine agonists: a neurophysiological study, Brain Res. 400, 205.
9. Cheng, Y.C. and W.H. Prusoff, 1973, Relationship between the inhibition constant and the concentration of inhibitor which causes 50 percent inhibition of an enzymatic reaction, Biochem. Pharmacol. 22, 3099.
10. Chio, C.L., G.F. Hess, R.S. Graham and R.M. Huff, 1990, A second molecular form of D2 dopamine receptor in rat and bovine caudate nucleus, Nature 343, 266.
11. Chio, C.L., M.E. Lajiness and R.M. Huff, 1994a, Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors, Mol. Pharmacol. 45, 51.
12. Chio, C.L., R.F. Drong, D.T. Riley, G.S. Gill, J.L. Slightom and R.M. Huff, 1994b, D4 dopamine receptor-mediated signaling events determined in transfected Chinese hamster ovary cells, J. Biol. Chem. 269, 11813.
13. Clark, D., G. Engberg, E. Pileblad, T.H. Svensson, A. Carlsson, A.S. Freeman and B.S. Bunney, 1985, An electrophysiological analysis of the actions of the 3-PPP enantiomers on the nigrostriatal dopamine system, Naunyn-Schmiedeberg's Arch. Pharmacol. 329, 344.
14. Cummings, J.L., 1992, Depression and Parkinson's disease: a review, Am. J. Psychiatry 149, 443.
15. Dolphin, A.C., 1987, Nucleotide binding proteins in signal transduction and disease, Trends Neurosci. 10, 53.
16. Eden, R.J., B. Costall, A.M. Domeney, P.A. Gerrard, C.A. Harvey, M.E. Kelly, R.J. Naylor D.A.A. Owen and A. Wright, 1991, Preclinical pharmacology of ropinirole (SK&F 101468-A), a novel dopamine D2 agonist, Pharmacol. Biochem. Behav. 18, 147.
17. Fargin, A., J.R. Raymond, M.J. Lohse, B.K. Kobilka, M.G. Caron and R.J. Lefkowitz, 1988, The genomic clone G-21 which resembles a β-adrenergic receptor sequence encodes the 5-HT1A receptor. Nature 335, 358.
18. Finney, D.J., 1978, Statistical Methods in Biological Assay (MacMillan Publishing Co., Inc., New York) p. 269.
19. 3 receptor and 7-OH-DPAT. Trends Pharmacol. Sci. 15, 173.
20. Gessa, G.L., 1988, Agonist and antagonist actions of lisuride on dopamine neurons: electrophysiological evidence, J. Neural Transm. S27, 201.
21. Goetz, C.G., 1990, Dopaminergic agonists in the treatment of Parkinson's disease, Neurology 40 (Suppl. 3), 50.
22. 3 receptors, Eur. J. Pharmacol. 372, R1.
23. Heym, J. and B.L. Jacobs, 1987, Serotonergic mechanisms of hallucinogenic drug effects, Monogr. Neural Sci. 13, 55.
24. Hjorth, S., A. Carlsson, D. Clark, K. Svensson, H. Wikstrom, D. Sanchez, P. Lindberg, U. Hacksell, L.E. Arvidsson and A. Johansson, 1983, Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP, Psychopharmacology, Berlin 81, 89.
25. Hubble, J.P., W.C. Koller, N. Cutler, J. Friedman, C. Goetz, A. Ranhosky, D. Korts and A. Elvin, 1995, Pramipexole, a highly selective dopamine agonist, in patients with early Parkinson's disease: an ascending-dose trial, Clin. Neuropharmacol. 18, 338.
26. Hyslop, D.K., W.E. Hoffmann, M.W. Smith and M.F. Piercey, 1993, Excitation of anterior caudate neurons by stimulation of D3 receptors, Neurosci. Abstr. 19, 80.
27. Lahti R.A., D.L. Evans, L.M. Figur, R.M. Huff and M.W. Moon, 1991, Pre- and postsynaptic dopaminergic activities of U-86170F, Naunyn-Schmiedeberg's Arch. Pharmacol. 344, 509.
28. Lahti, R.A., L.M. Figur, M.F. Piercey, P.L. Ruppel and D.L. Evans, 1992, Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: Utilization of receptor binding affinities, Mol. Pharmacol. 42, 432.
29. Langtry, H.D. and S.P. Clissold, 1990, Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease, Drugs 39, 491.
30. 3H]hydroxy-N,N-di-n-propyl-2-aminotetralin, Proc. Natl. Acad. Sci. USA 89, 8155.
31. 3 receptor agonist 7-OH-DPAT: lack of mesolimbic selectivity, Eur. J. Pharmacol. 264, 269.
32. Meller, E., E. Helmer-Matyjek, K. Bohmaker, C.H. Adler, A.J. Friedhoff and M. Goldstein, 1986, Receptor reserve at striatal dopamine autoreceptors: implications for selectivity of dopamine agonists, Eur. J. Pharmacol. 123, 311.
33. Mierau, J. and G. Schingnitz, 1992. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist, Eur. J. Pharmacol. 215, 161.
34. 4 receptors, Eur. J. Pharmacol. 290, 29.
35. Montastruc, J.L., O. Rascol and J.M. Senard, 1993, Current status of dopamine agonists in Parkinson's disease management. Drugs 46, 384.
36. Olanow, C.W., 1988, Single-blind double observer-controlled study of carbidopa/levodopa vs. BCT in untreated Parkinson patients, Arch. Neurol. 45, 206.
37. Piercey M.F., W.E. Hoffmann, G.D. Vogelsang and M. Travis, 1987, Electrophysiological evaluation of a partial agonist of dopamine receptors, J. Pharmacol. Exp. Ther. 243, 391.
38. Piercey, M.F., M.W. Smith and J.T. Lum, 1994, Excitation of noradrenergic cell firing by 5-HT1A agonists correlates with dopamine antagonist properties, J. Pharmacol. Exp. Ther. 268, 1297.
39. Piercey, M.F., D.K. Hyslop and W.E. Hoffmann, 1996, Excitation of type II caudate neurons by systemic administration of dopamine agonists, Brain Res. 706, 249.
40. Rabey, J.M., P. Passeltiner, K. Markey, T. Asano and M. Goldstein, 1981, Stimulation of pre-and postsynaptic dopamine receptors by an ergoline and by a partial ergoline, Brain Res. 225, 347.
41. Rogawski, M.A. and G.K. Aghajanian, 1979, Response of central monoaminergic neurons to lisuride: comparison with LSD, Life Sci. 24, 1289.
42. Scarnati, E., C. Forchetti, G. Ciancarelli, C. Pacitti and A. Agnoli, 1980, Dopaminergic and non-dopaminergic neurons in substantia nigra: differential response to bromocriptine, J. Neural Transm. 48, 297.
43. Schilling, J.C., W.S. Adamus and R. Palluk, 1992, Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans, Clin. Pharmacol. Ther. 51, 541.
44. 3) as a target for neuroleptics, Nature 347, 146.
45. 1 receptor locus to an intronless gene on chromosome 5, Nature 347, 80.
46. Svensson, K., A. Ekman, M.F. Piercey, W.E. Hoffmann, J.T. Lum and A. Carlsson, 1991, Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors, Naunyn-Schmiedeberg's Arch. Pharmacol. 344, 263.
47. 3 receptors, Eur. J. Pharmacol. 263, 235.
48. Wachtel, H., 1991, Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animals and humans, J. Neural Trans. 3[P-D Sect], 151.
49. 3H]-(±)-7-OH-DPAT and carbetapentane, J. Neurochem. 64, 700.
50. 3-preferring compound that lacks interactions with sigma binding sites, Neurosci. Res. Commun. 17, 177.
51. Waters, N., K. Svensson, S.R. Haadsma-Svensson, M.W. Smith and A. Carlsson, 1993, The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity, J. Neural Trans. 94, 11.
52. Watson, S. and Girdlestone, D., 1995, Receptor and Ion Channel Nomenclature Supplement, Trends Pharmacol. Sci. (Elsevier, Amsterdam) p. 26.
53. Willner, P., S. Lappas, S. Cheeta and R. Muscat, 1994, Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole, Psychopharmacology 115, 454.
54. Yahr, M.D., 1993, Parkinson's disease: new approaches to diagnosis and treatment, Neurol. Scand. 87 (Suppl. 146), 22.
55. Yarbrough, G.G., J. McGuffin-Clineschmidt, D.K. Singh, D.R. Haubrich, R.J. Bendesky and G.E. Martin, 1984, Electrophysiological, biochemical, and behavioural assessment of dopamine autoreceptor activation by a series of dopamine agonists, Eur. J. Pharmacol. 99, 73.